Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo

Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the market and potential setbacks in its drug pipeline. I believe that BMY is undervalued compared to its peers, and I am adding to my position in the company.

Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84%

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO24--Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or.

Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Bristol Myers Squibb (BMY) closed the most recent trading day at $41.77, moving +1.65% from the previous trading session.

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS' Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting.

Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting

Chevron

Enbridge

Enterprise Products Partners

Energy Transfer LP Unit

Kinder Morgan

Eli Lilly

National Retail Properties

Novo Nordisk

Realty Income Corp

Pfizer

Prologis

Rexford Industrial Realty

W. P. Carey

Exxon Mobil

Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and income investors can potentially achieve a high level of success by buying quality undervalued companies that pay dividends. In this article, I highlight high-yielding names in REITs, Energy, and Healthcare that I find attractive at present.

Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations.

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

AT&T

Dividend-paying stocks tend to outperform their non-dividend-paying cousins. Bristol Myers Squibb is a leading pharmaceutical company that has raised its dividend payout for 15 consecutive years.

2 No-Brainer Dividend Stocks You Can Buy With $100 in June

S&P 500 operating EPS growth was solid at 6.4% in Q1, but critics argue that excluding profits from top tech stocks shows less impressive growth. Bristol-Myers Squibb faces a soft growth outlook, but high expected free cash flow and steady sales suggest today's valuation is simply too low. With a dividend yield now near 6%, I outline key price levels to monitor in this beaten-down pharma stock.

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Treatment with Bristol Myers Squibb's immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday.

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO24--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced.

KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer

Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.

Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion

The U.S. Food and Drug Administration has allowed expanded use of Bristol Myers Squibb's cell therapy, Breyanzi, for an aggressive and rare type of blood cancer that affects the body's disease fighting cells, the company said on Thursday.

US FDA allows use of Bristol's cell therapy for rare blood cancer

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Adobe

Autodesk

Baidu

Corpay Inc

Global Payments

Medifast

Whether investors refer to them as undervalued or hidden gems, underappreciated stocks are always worth considering. Investors have made fortunes, large and small, by identifying underappreciated shares and investing their capital.

7 Underappreciated Stocks With 25% Return Potential in 2024

In trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.

Bristol Myers Squibb Shares Cross 6% Yield Mark

Civitas Resources

Cisco Systems

Gilead Sciences

NIKE

Declining U.S. interest rates will boost yield-paying shares.

2024 is being called ‘the year of the dividend.' These 5 stocks keep on giving.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line.

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

SAN FRANCISCO--(BUSINESS WIRE)-- #CADD--Menten AI, Inc., a biotechnology company with a generative AI platform for design and optimization of peptide macrocycles, today announced the completion of a previously undisclosed research collaboration and licensing agreement with Bristol Myers Squibb applying Menten AI's platform for optimization of cyclic peptides. Menten AI's platform combines state-of-the-art machine learning techniques with physics-based models and quantum chemistry simulations to acceler.

Menten AI Announces Completion of Research Collaboration with Bristol Myers Squibb

It may seem risky to look for blue-chip stocks at a 52-week low. After all, most blue chips are renowned for their ability to trade within a stable range and deliver growth.

3 Blue-Chip Stocks to Buy at 52-Week Lows in May

MPLX

Buying quality companies at attractive valuations with post-inflation income may be a winning strategy. Bristol Myers Squibb stock is trading below its value 10 years ago, with a 6% yield and promising pipeline. MPLX LP stock is also trading below its value 10 years ago, with an 8.5% yield and strong cash flows from energy assets.

I'm Buying The Dip On These 6-9% Yields

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications.

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Novartis

Targeted radiopharmaceuticals has caught the eye of big pharma. The therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.

News for Bristol-Myers Stock (BMY)